Compare Meta Platforms Inc (META) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Novavax Inc — how do they compare? Meta Platforms Inc trades at $585.81 (market cap $1.53T), while Novavax Inc trades at $7.89 (market cap $1.31B). The key difference: Meta Platforms Inc is far larger — about 1167.9× Novavax Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| META | NVAX | |
|---|---|---|
Market Cap | $1.53T | $1.31B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $11.19 |
52-Week Low | $525.72 | $6.22 |
Enterprise Value | $1.55T | $889.30M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed ($6.18 vs $7.19). Technical indicators show bearish signals with current price near pivot point resistance at $598. The company maintains robust cash flow generation of $115.8B from operations in 2025.
Analyst consensus remains strongly bullish with 79% buy ratings and $761.95 price target, representing 28% upside. Key catalysts include AI leadership with Muse Spark launch and strong revenue growth trajectory. Risks include regulatory lawsuits, high capital expenditures, and competitive pressures in social media and AI markets.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
